Skip to content

News

Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America

(Stockholm, May 5, 2023) On May 19, 2023 Asarina Pharma’s positive results from its Phase IIa Study in Tourette Syndrome will be presented at TicCon, the Virtual National Conference of the Tourette Association of America, by Assoc. Prof. Marco Bortolato (Dept Pharmacology & Toxicology, University of Utah). The results were an important target validation of…

Full PDF

Asarina Pharma AB (publ) releases Annual Report 2022

(Stockholm, 28 April 2023) Asarina Pharma’s 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results for Tourette syndrome, as well as 2022 financial statements and outlook. Additional content includes investor FAQs with CEO Peter Nordkild and clinical insights from Clinical Neurologist Dr Heidi Biernat (Head of the Tourette Clinic at…

Full PDF

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

The shareholders of Asarina Pharma AB (publ) reg. no. 556698-0750 (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 22 May 2023 at 10:00 CEST at Fredersen Advokatbyrå's premises at Birger Jarlsgatan 8, Stockholm. Registration starts at 09:30 CEST.

Full PDF

Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome

(Stockholm, April 1, 2023) Asarina Pharma today releases results from its Phase IIa study of the endogenous neurosteroid Sepranolone for the treatment of Tourette Syndrome. The primary objective of the study was to investigate the efficacy of Sepranolone, compared to Standard of Care, to reduce tic severity in patients with Tourette Syndrome at twelve weeks,…

Full PDF

Asarina Pharma AB (publ) releases Year-End Report 2022

(Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 the company continued its Phase IIa study in Sepranolone for Tourette Syndrome, on schedule, completing Last Patient Last Visit on February 1, less than 12 months after commencement. The patient dropout rate…

Full PDF
Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders 2023-05-23 09:02
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) 2023-05-22 11:15
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America 2023-05-05 13:33
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Annual
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) 2023-04-18 10:39
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome 2023-04-01 14:20
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
Last Patient Last Visit for landmark Tourette Syndrome study 2023-02-02 09:45
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Patient recruitment completed in landmark Tourette syndrome study 2022-10-14 09:50
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD 2022-10-06 08:30
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
Next